Karuna Therapeutics, Inc., A Bristol Myers Squibb Company
Clinical trials sponsored by Karuna Therapeutics, Inc., A Bristol Myers Squibb Company, explained in plain language.
A subsidiary of Bristol Myers Squibb, focused on developing treatments for psychiatric and neurological disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aims to keep schizophrenia in check
Disease control Not yet recruitingThis phase 3 trial tests whether KarXT (a combination of xanomeline and trospium chloride) can prevent relapse in people with schizophrenia. Participants who have had a recent hospitalization for schizophrenia and still have symptoms will receive KarXT or a placebo. The study mea…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can Anti-Nausea meds tame KarXT's stomach woes?
Symptom relief Not yet recruitingThis study tests whether taking anti-nausea medication alongside KarXT—a drug used for schizophrenia—can reduce nausea and vomiting. Healthy volunteers will take KarXT with either scheduled or as-needed antiemetics. The goal is to find a safer, more comfortable way to start treat…
Phase: PHASE4 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC